
June 16 (Reuters) - DND Pharmatech Inc 347850.KQ:
D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH
D&D PHARMATECH ANNOUNCES POSITIVE PHASE 2 RESULTS FOR DD01 IN MASH WITH ROBUST REDUCTIONS IN LIVER FAT ACCOMPANIED BY IMPROVEMENTS IN LIVER AND METABOLIC HEALTH
DND PHARMATECH INC - 75.8% OF DD01-TREATED SUBJECTS ACHIEVED AT LEAST 30% REDUCTION IN LIVER FAT
DND PHARMATECH INC - DD01 TREATMENT ASSOCIATED WITH 62.3% RELATIVE REDUCTION IN LIVER FAT
DND PHARMATECH INC - DD01 WELL TOLERATED WITH MILD TO MODERATE GI SIDE EFFECTS
DND PHARMATECH INC - DD01 TREATMENT RESULTED IN SIGNIFICANT REDUCTIONS IN HBA1C AND BODY WEIGHT
DND PHARMATECH INC - ONLY 3 SUBJECTS DISCONTINUED DD01 TREATMENT DUE TO GI SIDE EFFECTS